{
  "pmcid": "7270872",
  "sha256": "5ab1bdc02ac7cbc1c3ef0fe1b15024d0a94ebff59c70a8703f86c6e24ca94c63",
  "timestamp_utc": "2025-11-10T00:05:13.887652+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.697263917061079,
    "reading_ease": 45.713833671399584,
    "word_count": 261
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Roux-en-Y Gastric Bypass vs Best Medical Treatment in Patients with Type 2 Diabetes and Early-Stage CKD"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This single-center, randomised controlled trial was conducted from April 1, 2013, to March 31, 2016, involving 100 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "involving 100 patients with type 2 diabetes, obesity (BMI 30-35), and stage G1 to G3 and A2 to A3 CKD"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to receive Roux-en-Y gastric bypass (RYGB) or best medical treatment"
      },
      "Objective": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was remission of albuminuria (uACR <30 mg/g) at 24 months"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed"
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not applied to patients or clinicians"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 51 patients were randomised to RYGB and 49 to best medical treatment"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Intention-to-treat analysis revealed albuminuria remission"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "82% (95% CI, 72%-93%) of RYGB patients compared to 55% (95% CI, 39%-70%) in the control group (P = .006)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant difference in the rate of serious adverse events was observed between groups"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under ClinicalTrials.gov Identifier NCT01821508"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding sources were not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  }
}